The Indian Contract Research Organizations (CRO) market is currently witnessing robust growth and offers significant potential. With its strong scientific expertise, favorable regulatory environment, cost advantages, and diverse patient population, India has become an appealing destination for outsourcing research and development activities. Lambda Therapeutic Research is a standout player in the dynamic CRO market, offering comprehensive global solutions to the pharmaceutical, biotech, and generic industries.
Headquartered in India, it has a strong presence in the USA, Canada, the UK, and Poland. In North America, Lambda operates under the unified brand of Novum Pharmaceutical Research Services, a 50-year-old CRO and fully owned subsidiary of Lambda. Lambda effectively addresses various challenges in the dynamic landscape of drug development, offering a comprehensive range of clinical research services covering the Early phase (First-in-Man studies, BA/BE Studies), Late Phase, Bioanalytical and Large Molecules, Biosimilars & Peptide Studies, and Assay Development, Central clinical lab services, Medical Imaging analysis, Biostatistics and Data management, Drug Safety and Pharmacovigilance, as well as Medical Writing support globally. Lambda specializes in Medical Imaging services for oncology (RECIST 1.1 and Cheson 2014), Musculoskeletal (DXA and X-ray), and Ophthalmology (CFP, FA, and OCT) evaluations, and has plans for expansion into iRECIT evaluation and Gastrointestinal Imaging.
Their in-house developed DISoft application is 21 CFR part 11, PHI, GDPR, and GxP compliant, ensuring secure uploading, analysis, and storage of clinical trial images. Lambda ensures comprehensive pharmacovigilance support throughout the life cycle of medicinal products. In 2022, Lambda processed over 86,000 cases and conducted more than 650,000 literature screenings using PvEdge, their web-based safety database, which includes modules like LAM, PrITR, and PvD'code for efficient case processing, literature review, and adverse event data management. "We have invested heavily in building up a team of 1500+ professionals while also placing equal emphasis on implementing cutting-edge digital platforms, secure IT Infrastructure, and automation across all our systems and processes, keeping the current global regulatory requirements in perspective”, says Bindi Chudgar, Founder & MD, Lambda Therapeutic Research.
Standing Out
Lambda currently stands as a leading CRO globally, distinguishing itself through its core USP of Digitization & Automation, along with its global technical expertise and talented workforce. "We ensure timely project delivery with experienced teams, robust processes, and adherence to global regulatory standards. Our high-quality standards and compliance are maintained through a robust quality management system, resulting in an exceptional regulatory track record.
Over the past five years, we have successfully completed 60+ international inspections and audits by esteemed regulatory authorities, including USFDA, EMEA, MHRA, EU member states, and other global bodies", says Bindi Chudgar. “With 7000+ BA/BE studies, 215+ Late phase studies, and over 65,000 patients enrolled worldwide, we have established a strong presence across the USA, Europe, and Pan-India through our network of clinical sites. Our specialization in oncology, combined with our teams' proficiency in diverse domains, allows us to provide tailored support that aligns with each client's specific needs", she adds.
Revolutionizing clinical research through innovation & collaboration
Future Projections
Lambda's future roadmap prioritizes innovation and expansion, with a specific focus on enhancing capabilities in Biosimilar, Large Peptides/ADCs, and Oncology Late Phase Clinical Trials. By forming strategic alliances, Lambda aims to provide comprehensive solutions and drive meaningful advancements in healthcare. With a target of reaching revenues of $130 million by FY 2025- 26 and a projected compound annual growth rate of 28 percent YoY, Lambda is poised to lead and shape the future of contract research organizations in India and globally.
